Growth hormone-releasing peptides and their analogs

Frontiers in Neuroendocrinology

Volumn 19, Issue 1, 1998, Pages 47-72

  Camanni, Franco ^a   Ghigo, Ezio ^b   Arvat, Emanuela ^b  

^a MOLINETTE HOSPITAL   (Italy)

^b NONE

Author keywords

Aging; Catabolic states; GH; GH deficiency; GH secretagogues; GHRP

Indexed keywords

3 (2 HYDROXYPROPYLAMINO) 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; 3 AMINO 3 METHYL N [2,3,4,5 TETRAHYDRO 2 OXO 1 [[2' (1H TETRAZOL 5 YL) 1,1' BIPHENYL 4 YL]METHYL] 1H 1 BENZAZEPIN 3 YL]BUTANAMIDE; ACIPIMOX; ARGININE; ATENOLOL; CLONIDINE; CORTICOTROPIN; FATTY ACID; GLUCOSE; GROWTH HORMONE; GROWTH HORMONE RELEASING FACTOR; GROWTH HORMONE RELEASING FACTOR DERIVATIVE; GUANINE NUCLEOTIDE BINDING PROTEIN; HEXARELIN; HYDROCORTISONE; IBUTAMOREN; NEUROTRANSMITTER; PIRENZEPINE; PROLACTIN; PYRIDOSTIGMINE; RECOMBINANT GROWTH HORMONE; SALBUTAMOL; SOMATOSTATIN; UNCLASSIFIED DRUG;

ACROMEGALY; ADOLESCENT; ADULT; AGED; AGING; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HEART DILATATION; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; INFANT; INTRANASAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEWBORN; NONHUMAN; OBESITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; REVIEW; SHORT STATURE; SIGNAL TRANSDUCTION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031893129     PISSN: 00913022     EISSN: None     Source Type: Journal    
DOI: 10.1006/frne.1997.0158     Document Type: Article

References (172)

1. Adams EF, Petersen B, Ting L, Buchfelder M, Fahlbusch R. The growth hormone secretagogue, L-692,429, induces phosphatidylinositol hydrolysis and hormone secretion by human pituitary tumors. Biochem Biophys Res Commun 1995; 208: 555-561.
2. Akman MS, Girard M, O'Brien L, Ho AK, Chik CL. Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-βNal-Ala-Trp-D-Phe-Lys-NH2) in rat anterior pituitary cells. Endocrinology 1993; 132: 1286-1291.
3. Aloi JA, Gertz BJ, Hartman ML, Huhn WC, Pezzoli SS, Wittreich M, Krupa DA, Thorner MO. Neuroendocrine responses to a novel growth hormone secretagogue, L-692,429, in healthy older subjects. J Clin Endocrinol Metab 1994; 79: 943-949.
4. Alster DK, Bowers CY, Jaffe CA, Ho PJ, Barkan AL. The growth hormone (GH) response to GH-releasing peptide (His-D-Trp-Ala-Trp-D-Phe-Lys-NH2), GH-releasing hormone, and thyrotropin-releasing hormone in acromegaly. J Clin Endocrinol Metab 1993; 77: 842-845.
5. Arosio M, Biella O, Casati G, Guglielmino L, Palmieri E, Faglia G. Effects of Hexarelin (EP23905-MF6003) on circulating GH levels in acromegalic patients. (Highlights in Mol Clin Endocrinol). Front Endocrinol 1994; 9: 151-154.
6. Arvat E, Gianotti L, Grottoli S, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E. Arginine and growth hormone-releasing hormone restore the blunted growth hormone-releasing activity of hexarelin in elderly subjects. J Clin Endocrinol Metab 1994; 79: 1440-1443.
7. Arvat E, Gianotti L, Di Vito L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F, Ghigo E. Modulation of growth hormone-releasing activity of hexarelin in man. Neuroendocrinology 1995; 61: 51-56.
8. Arvat E, Di Vito L, Gianotti L, Ramunni J, Boghen MF, Deghenghi R, Camanni F, Ghigo E. Mechanisms underlying the negative growth hormone (GH) autofeedback on the GH-releasing effect of Hexarelin in man. Metabolism 1997; 46: 83-88.
9. Arvat E, Ceda GP, Ramunni J, DiVito L, Gianotti L, Boghen MF, Deghenghi R, Ghigo E. Supramaximal doses of GHRH or Hexarelin, a synthetic hexapeptide, enhance the low somatotrope responsiveness in aging. J Endocrinol Invest 1996; 19(Suppl. 5): 3.
10. Arvat E, Gianotti L, Ramunni J, Di Vito L, Deghenghi R, Camanni F, Ghigo E. Influence of beta-adrenergic agonists and antagonists on the GH-releasing effect of Hexarelin in man. J Endocrinol Invest 1996; 19: 25-29.
11. Arvat E, Gianotti L, Broglio F, Maccagno B, Bertagna A, Deghenghi R, Camanni F, Ghigo E. Oestrogen replacement does not restore the reduced GH-releasing activity of hexarelin, a synthetic hexapeptide, in postmenopausal women. Eur J Endocrinol 1997; 136: 483-487.
12. Arvat E, Maccagno B, Ramunni J, Gianotti L, Di Vito L, Deghenghi R, Camanni F, Ghigo E. Effects of histaminergic antagonists on the GH-releasing activity of GHRH or hexarelin, a synthetic hexapeptide, in man. J Endocrinol Invest 1997; 20: 122-127.
13. Arvat E, Di Vito L, Maccagno B, Broglio F, Boghen MF, Deghenghi R, Camanni F, Ghigo E. Effects of GHRP-2 and Hexarelin, two synthetic GH-releasing peptides, on GH, prolactin, ACTH and cortisol level in man. Comparison with the effects of GHRH, TRH, and hCRH. Peptides, 1997; 18: 885-891.
14. Badger TM, Millard WY, McCormik GF, Bowers CY, Martin JB. The effects of growth hormone (GH)-releasing peptides on GH secretion in perifused pituitary cells of adult male rats. Endocrinology 1984; 115: 1432-1438.
15. Blake AD, Smith RG. Desensitization studies using perifused rat pituitary cells show that growth hormone-releasing hormone and His-D-Trp-D-Phe-Lys-NH2 stimulate GH release through different receptor sites. J Endocrinol 1991; 129: 11-19.
16. Bellone J, Aimaretti G, Bartolotta E, Benso L, Imbimbo BP, Lenhaerts V, Deghenghi R, Camanni F, Ghigo E. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, before and during puberty. J Clin Endocrinol Metab 1995; 80: 1090-1094.
17. Bellone J, Ghizzoni L, Aimaretti G, Volta C, Boghen MF, Bernasconi S, Ghigo E. Growth hormone-releasing effect of oral growth hormone-releasing peptide 6 (GHRP-6) administration in children with short stature. Eur J Endocrinol 1995; 133: 425-429.
18. Bercu BB, Weideman CA, Walker RF. Sex differences in growth hormone (GH) secretion by rats administered GH-releasing hexapeptide. Endocrinology 1991; 129: 2592-2598.
19. Bereu BB, Yang SW, Masuda R, Walker RF. Role of selected endogenous peptides in growth hormone-releasing hexapeptide activity: Analysis of growth hormone-releasing hormone, thyroid hormone-releasing hormone, and gonadotropin-releasing hormone. Endocrinology 1992; 130: 2579-2586.
20. Bitar KG, Bowers CY, Coy DH. Effect of substance P/bombesin antagonists on the release of GH by GHRP and GHRH. Biochem Biophys Res Commun 1991; 5: 156-161.
21. Bowers CY, Momany FA, Reynolds GA, Hong A. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone. Endocrinology 1984; 114: 1537-1545.
22. Bowers CY, Reynolds GA, Durham D, Barrera CM, Pezzoli SS, Thorner MO. Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab 1990; 70: 975-982.
23. Bowers CY, Sartor AO, Reynolds GA, Badger TM. On the action of the growth hormone-releasing hexapeptide, GHRP. Endocrinology 1991; 128: 2027-2035.
24. Bowers CY, Alster DK, Frentz JM. The growth hormone-releasing activity of a synthetic hexapeptide in normal men and short statured children after oral administration. J Clin Endocrinol Metab 1992; 74: 292-298.
25. Bowers CY, Veeraragavan K, Sethumadhavan K. Atypical growth hormone releasing peptides. In: Bercu BB, Walker RF, Eds. Growth Hormone II, Basic and Clinical Aspects. Springer-Verlag: New York, 1993: 203-222.
26. Bowers CY GH releasing peptides: Structure and kinetics. J Pediatr Endocrinol 1993; 6: 21-31.
27. Bowers CY Novel GH-releasing peptides. In: Melmed S Ed. Molecular and Clinical Advances in Pituitary Disorders. Los Angeles: Endocr Res Educ, INC, 1993: 153.
28. Cappa M, Setzu S, Bernardini S, Carta D, Federici G, Grossi A, Loche S. Exogenous growth hormone administration does not inhibit the growth hormone response to Hexarelin in normal men. J Endocrinol Invest 1995; 18: 762-766.
29. Casanueva FF. Physiology of growth hormone secretion and action. In: Melmed S, Ed. Endocrinology and Metabolism Clinics of North America. Philadelphia, Saunders, 1992: 483-517.
30. Cella S, Locatelli V, Poratelli M, De Gennaro Colonna V, Imbimbo BP, Deghenghi R, Muller EE. Hexarelin, a potent GHRP analogue: Interaction with GHRH and clonidine in young and aged dogs. Peptides 1995; 16: 81-86.
31. Chang CH, Rickes EL, Marsilio F, McGuire L, Cosgrove S, Taylor J, Chen H, Feighner S, Clark JN, De Vita R, Schoen W, Wyvratt M, Fisher M, Smith RG, Hickey GJ. Activity of a novel non peptidyl GH secretagogue, L-700,653, in swine. Endocrinology 1995; 136: 1065-1071.
32. th International Congress of Endocrinology, San Francisco 1996: 486.
33. Chapman IM, Bach MA, Van Cauter E, Farmer M, Krupa D, Taylor AM, Schilling LM, Cole KY, Skiles EH, Pezzoli SS, Hartman ML, Veldhuis JD, Gormley GJ, Thorner MO. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretagogue (MK-677) in healthy elderly subjects. J Clin Endocrinol Metab 1996; 81: 4249-4257.
34. Chapman IM, Hartman ML, Pezzoli SS, Thorner MO. Enhancement of pulsatile growth hormone secretory by continous infusion of a growth hormone-releasing peptide mimetic, L-692,429, in older adults - A clinical research center study. J Clin Endocrinol Metab 1996; 81: 2874-2880.
35. th International Congress of Endocrinology, San Francisco 1996: 769.
36. Chatelain P, Claris O, Lapillonne A, Dimayo M, Salle B. Fetal and neonatal somatotroph function. Front Paediatr Neuroendocrinol 1994; 20: 127-130.
37. Cheng K, Chan WW, Barreto A, Convey EM, Smith RG. The synergistic effects of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on growth hormone (GH)-releasing factor-stimulated GH release and intracellular adenosine 3′,5′-monophosphate accumulation in rat primary cell culture. Endocrinology 1989; 124: 2791-2798.
38. Cheng K, Chan WW, Butler B, Wei L, Smith RG. A novel non-peptidyl growth hormone secretagogue. Harm Res 1993; 49: 109-115.
39. Cheng K, Chan WW, Butler B, Wei L, Schoen WR, Wyratt MJ, Fisher MH, Smith RG. Stimulation of growth hormone release from rat primary pituitary cells by L-692,429, a novel non-peptidyl GH secretagogue. Endocrinology 1993; 132: 2729-2731.
40. Chihara K, Kaji H, Hayashi S, Yagi H, Takeshima Y, Mitani M, Ohashi SI, Abe H. Growth hormone releasing hexapeptide: Basic research and clinical application. In: Bercu BB, Walker RF, Eds. Growth Hormone II, Basic and Clinical Aspects. Springer-Verlag, New York, 1993: 203-222.
41. Ciccarelli E, Grottoli S, Razzore P, Gianotti L, Arvat E, Deghenghi R, Camanni F, Ghigo E. Hexarelin, a synthetic growth hormone releasing peptide, stimulates prolactin secretion in acromegalic but not in hyperprolactinemia patients. Clin Endocrinol 1996; 44: 67-71.
42. Clark RG, Carlsson MS, Trojnar J, Robinson ICAF. The effects of a growth hormone-releasing peptide and growth hormone-releasing factor in conscious and anaesthetized rats. J Neuroendocrinol 1989; 1: 249-255.
43. th International Congress of Endocrinology, San Francisco 1996; 282.
44. Codd EE, Yellin T, Walker RF. Binding of growth hormone-releasing hormone and enkephalin-derived growth hormone-releasing peptides to mu and delta opioid receptors in forbrain of rat. Neuropharmacology 1988; 27: 1019-1025.
45. Codd EE, Shu AYL, Walker RF. Binding of a growth hormone releasing hexapaptide to specific hypothalamic and pituitary binding sites. Neuropharmacology 1989; 28: 1139-1144.
46. Conley LK, Teik JA, Deghenghi R, Imbimbo BP, Giustina A, Locatelli V, Wehrenberg WB. Mechanism of action of Hexarelin and GHRP-6: Analysis of the involvement of GHRH and somatostatin in the rat. Neuroendocrinology 1995; 61: 44-50.
47. Copinschi G, van Onderbergen A, L'hermite-Baleriaux M, Mendel CM, Caufriez A, Leproult R, Bolognese JA, De Smet M, Thorner MO, van Cauter E. Effects of 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men. J Clin Endocrinol Metab 1996; 81: 2776-2782.
48. Cordido F, Penalva A, Dieguez C, Casanueva FF. Massive growth hormone (GH) discharge in obese subjects after the combined administration of GH-releasing hormone and GHRP-6: Evidence for a marked somatotroph secretory capability in obesity. J Clin Endocrinol Metab 1993; 76: 819-823.
49. Cordido F, Penalva A, Peino R, Casanueva FF, Dieguez C. Effect of combined administration of growth hormone (GH)-releasing hormone, GH-releasing peptide-6 and pyridostigmine in normal and obese subjects. Metabolism 1995; 44: 745-748.
50. Cordido F, Peino R, Penalva A, Alvarez CV, Casanueva FF, Dieguez C. Impaired growth hormone secretion in obese subjects is partially reversed by acipimox-mediated plasma free fatty acid depression. J Clin Endocrinol Metab 1996; 81: 914-918.
51. Corpas E, Harman SM, Blackman G. Human growth hormone and human aging. Endocr Rev 1993; 14: 20-39.
52. DeBell WK, Pezzoli SS, Thorner MO. Growth hormone (GH) secretion during continuous infusion of GH-releasing peptide: Partial response attenuation. J Clin Endocrinol Metab 1991; 72: 1312-1316.
53. Deghenghi R. Growth hormone releasing peptides. In: Bercu B, Walker R, Eds. Growth Hormone Secretagogues. Serono Symposia, New York, 1993: 85-102.
54. Deghenghi R, Cananzi M, Torsello A, Battisti C, Muller EE, Locatelli V. GH-releasing activity of Hexarelin, a new growth hormone releasing peptide, in infant and adult rats. Life Sci 1994; 54: 1321-1328.
55. Deghenghi R, Boutignon F, Luoni M, Grilli R, Guidi M, Locatelli V. Small peptides as potent releasers of growth hormone. J Ped Endocrinol Metab 1995; 8: 311-313.
56. th International Congress of Endocrinology, San Francisco 1996: 280.
57. DeVita RJ, Wyvratt MJ. Benzolactam growth hormone secretagogues. Drugs Future 1996; 21: 273-281.
58. Dickson SL, Leng G, Dyball REJ, Smith RG. Central actions of peptide and non-peptide growth hormone secretagogues in the rat. Neuroendocrinology 1995; 61: 36-43.
59. Dickson SL, Doutrelant-Viltart O, Leng G. GH-deficient dw/dw rats and lit/lit mice show increased Fos expression in the hypothalamic arcuate nucleus following systemic injection of GH-releasing peptide-6. J Endocrinol 1995; 146: 519-526.
60. Dieguez C, Mallo F, Senaris R, Pineda J, Martul P, Leal-Cerro A, Pombo M, Casanueva FF. Role of glucocorticoids in the neuroregulation of growth hormone secretion. J Pediatr Endocrinol Metab 1996; 9: 255-260.
61. Doscher ME, Baker PK, Kraft LA, Ricks CA. Effect of a synthetic growth hormone releasing hexapeptide (BI 679) and growth hormone releasing factor (GRF) on serum growth hormone levels in barrows. J Anim Sci 1984; 59: 218.
62. Dubreuil P, Petitclerc D, Pelletier G, Gaudeau P, Farmer C, Mowles TF, Brezean P. Effect of dose and frequency of administration of a potent analog of human growth hormone-releasing factor on hormone secretion in pigs. J Anim Sci 1990; 68: 1254-1268.
63. Edwards CA, Dieguez C, Scanlon MF. Effects of hypothyroidism, tri-iodothyronine and glucocorticoids on growth hormone responses to growth hormone-releasing hormone and His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. J Endocrinol 1989; 121: 31-36.
64. Elias KA, Ingle GS, Burnier JP, Hammonds RG, McDowell RS, Rawson TE, Somers TC, Stanley MS, Cronin MJ. In vitro characterization of four novel classes of growth hormone-releasing peptide. Endocrinology 1995; 136: 5694-5699.
65. Fairhall KM, Mynett A, Robinson ICAF. Central effects of growth hormone-releasing hexapeptide (GHRP-6) on growth hormone release are inhibited by central somatostatin action. J Endocrinol 1995; 144: 555-560.
66. Fairhall KM, Mynett A, Smith RG, Robinson ICAF. Consistent GH responses to repeated injections of GH-releasing hexapeptide (GHRP-6) and the non-peptide GH secretagogue, L-692,585. J Endocrinol 1995; 145: 417-426.
67. Fazio S, Sabatini D, Capaldo B, Vigorito C, Giordamo A, Guida R, Pardo F, Biondi B, Saccà L. A preliminary study of growth hormone in the treatment of dilated cardiomyopathy. N Engl J Med 1996; 334: 100-103.
68. Fletcher TP, Thomas GB, Willoughby JO, Clarke IJ. Constitutive growth hormone secretion in sheep after hypothalamopituitary disconnection and the direct in vivo pituitary effect of growth hormone releasing peptide 6. Neuroendocrinology 1994; 60: 76-86.
69. Frieboes RM, Murck H, Maier P, Schier T, Holsboer F, Steiger A. Growth hormone-releasing peptide-6 stimulates sleep, growth hormone, ACTH and cortisol release in normal man. Neuroendocrinology 1995; 61: 584-589.
70. Gelato MC, Pescovitz DH, Cassorla F, Loriaux DL, Merriam GR. Dose-response relationships for the effects of GH-releasing factor 1-44 NH2 in young adult men and women. J Clin Endocrinol Metab 1984; 59: 197-203.
71. Gertz BJ, Barrett JS, Eisenhandler R, Krupa DA, Wittreich JM, Seibold JR, Schneider SH. Growth hormone response in man to L-692,429, a novel non peptide mimic of growth hormone-releasing peptide-6. J Clin Endocrinol Metab 1993; 77: 1393-1397.
72. Gertz BJ, Sciberras DG, Yogendran L, Christie K, Bador K, Krupa D, Wittreich JM, James I. L-692,429, a non peptide growth hormone (GH) secretagogue reverses glucocorticoid suppression of GH secretion. J Clin Endocrinol Metab 1994; 79: 745-749.
73. Ghigo E. Neurotransmitter control of growth hormone secretion: In: de la Cruz LF Ed. Growth Hormone and Somatic Growth. Excerpta Medica; Amsterdam 1992; 103-136.
74. Ghigo E, Arvat E, Goffi S, Bellone J, Nicolosi M, Procopio M, Maccario M, Camanni F. Neural control of growth hormone secretion in aged humans. In: Muller EE, Cocchi D, Locatelli V, Eds. Growth Hormone and Somatomedins during Lifespan. Springer-Verlag, Berlin 1993: 275-287.
75. Ghigo E, Arvat E, Gianotti L, Imbimbo BP, Lenaerts V, Deghenghi R, Camanni F. Growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, after intravenous, subcutaneous, intranasal and oral administration in man. J Clin Endocrinol Metab 1994; 78: 693-698.
76. Ghigo E, Arvat E, Rizzi G, Bellone J, Nicolosi, Boffano GM, Boghen MF, Camanni F. Arginine enhances the growth hormone (GH)-releasing activity of a synthetic hexapeptide (GHRP-6) in elderly but not in young subjects after oral administration. J Endocrinol Invest 1994; 17: 157-162.
77. Ghigo E, Arvat E, Rizzi G, Goffi S, Mucci M, Boghen MF, Camanni F. Growth hormone-releasing activity of growth hormone-releasing peptide-6 is maintained after short-term oral pretreatment with the hexapeptide in normal aging. Eur J Endocrinol 1994; 131: 499-503.
78. Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Boghen MF, Deghenghi R, Camanni F. Short term administration of intranasal or oral hexarelin, a synthetic hexapeptide, does not desensitize the GH responsiveness in human aging. Eur J Endocrinol 1996; 135: 407-412.
79. Ghigo E, Arvat E, Gianotti L, Grottoli S, Rizzi G, Ceda GP, Deghenghi R, Camanni F. Aging and GH-releasing peptides. In: Bercu B, Walker R, Eds. Growth Hormone Secretagogues. Springer-Verlag, New York: 1996: 415-431.
80. th International Congress of Endocrinology, San Francisco 1996: 26.
81. Ghigo E, Arvat E, Ramunni J, Colao A, Gianotti L, Deghenghi R, Lombardi G, Camanni F. Adrenocorticotropin- and cortisol-releasing effect of hexarelin, a synthetic growth hormone-releasing peptide, in normal subjects and patients with Cushing's syndrome. J Clin Endocrinol Metab 1997; 89: 2439-2444.
82. Giustina A, Bussi AR, Deghenghi R, Imbimbo BP, Licini M, Poiesi C, Wehrenberg WB. Comparison of the effects of growth hormone-releasing hormone and hexarelin, a novel growth hormone-releasing peptide-6 analog, on growth hormone secretion in humans with or without glucocorticoid excess. J Endocrinol 1995; 146: 227-232.
83. th International Congress of Endocrinology, San Francisco 1996: 288.
84. Goth MI, Lyons CE, Canny BY, Thorner MO. Pituitary adenylate cyclase activating polypeptide, growth hormone (GH)-releasing peptide and GH-releasing hormone stimulate GH release through distinct pituitary receptors. Endocrinology 1992; 130: 939-944.
85. Grottoli S, Maccario M, Procopio M, Oleandri S, Razzore P, Taliano M, Camanni F, Ghigo E. Selective refractoriness of somatotrope secretion to the inhibitory effect of hyperglycemia in obesity. Eur J Endocrinol 1996; 135: 678-682.
86. Guillame V, Magnam E, Cataldi M, Dutour A, Sauze N, Renard M, Rezafindraibe H, Conte Devol B, Lenaertz V, Oliver C. Growth hormone (GH)-releasing hormone secretion is stimulated by a new GH-releasing hexapeptide in sheep. Endocrinology 1994; 135: 1073-1076.
87. Hanew K, Utsumi A, Sugawara A, Shimizu Y, Abe K. Enhanced GH responses to combined administration of GHRP and GHRH in patients with acromegaly. J Clin Endocrinol Metab 1994; 78: 509-512.
88. Hartman ML, Farello G, Pezzoli SS, Thorner MO. Oral administration of growth hormone (GH)-releasing peptide stimulates GH secretion in normal men. J Clin Endocrinol Metab 1992; 74: 1378-1384.
89. Hayashi S, Okimura Y, Yagi H, Uchiyama T, Takeshima S, Shakatsui S. Intranasal administration of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (growth hormone releasing peptide) increased plasma growth hormone and insulin-like growth factor-I levels in normal men. Endocrinol Jpn 1991; 38: 15-21.
90. Herrington J, Hille B. Growth hormone-releasing hexapeptide elevates intracellular calcium in rat somatotropes by two mechanisms. Endocrinology 1994; 135: 1100-1108.
91. Hickey GJ, Jacks T, Judith F, Taylor J, Schoen WR, Krupa D, Cunningham P, Clark J, Smith RG. Efficacy and specificity of L-692,429, a novel nonpeptidyl growth hormone secretagogue, in beagles. Endocrinology 1994; 134: 695-701.
92. Hickey GJ, Drisko J, Faidley T, Chang C, Anderson L, Nicolich S, McGuire L, Rickes E, Krupe D, Feeney W, Friscino B, Cunningham P, Frazier E, Chen H, Leroque P, Smith RG. Mediation by the central nervous system is critical to the in vivo activity of the GH secretagogue L-692,585. J Endocrinol 1996; 148: 371-380.
93. th International Congress of Endocrinology, San Francisco 1996: 285.
94. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Uamelin M, Ureniuk DI, Palyhe OC, Anderson J, Paress PS, Diaz C, Chou N, Liu KK, McKee KK, Pong SS, Cheung LY, Elbrecht A, Dashkevicz M, Keavehs R, Rishy M, Siringjhsinghji DJS, Dean DC, Melillo DG, Patchett AA, Nergund R, Srillin PR. A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 1996; 273: 974-977.
95. Huhn WC, Hartman ML, Pezzoli SS, Thorner MO. Twenty-four-hour growth hormone (GH)-releasing peptide (GHRP) infusion enhances pulsatile GH secretion and specifically attenuates the response to a subsequent GHRP bolus. J Clin Endocrinol Metab 1993; 76: 1202-1208.
96. Ilson BE, Jorkasky DK, Curnow RT, Stote RM. Effect of a new synthetic hexapeptide to selectively stimulate growth hormone release in healthy human subjects. J Clin Endocrinol Metab 1989; 69: 212-214.
97. Imbimbo BP, Mant T, Edward M, Amin D, Froud A, Lenaerts U, Boutignon F, Deghenghi R. Growth hormone releasing activity of hexarelin in humans: A dose-response study. Eur J Clin Pharmacol 1994; 46: 421-425.
98. th International Congress of Endocrinology, San Francisco 1996: 282.
99. Jacks T, Hickey G, Judith F, Taylor J, Chen H, Krupa D, Feeney W, Schoen W, OK Fisher M, Wyratt M, Smith R. Effects of acute and repeated intravenous administration of L-692,585, a novel non-peptidyl growth hormone secretagogue, on plasma growth hormone, IGF-I, ACTH, Cortisol, prolactin, insulin, and thyroxine levels in beagles. J Endocrinol 1994; 143: 399-406.
100. Jacks T, Smith R, Judith F, Schleim K, Frazier E, Chen H, Krupa D, Hora D, Nargund R, Patchett A, Hickey G. MK-0677, a potent novel, orally-active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles. Endocrinology 1996; 137: 5284-5289.
101. Jaffe CA, Ho PJ, Demott-Friberg R, Bowers CY, Barkan AL. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men. J Clin Endocrinol Metab 1993; 77: 1641-1647.
102. Klinger B, Silbergeld A, Deghenghi R, Frenkel J, Laron Z. Desensitization from long-term intranasal treatment with Hexarelin does not interfere with the biological effects of this growth hormone-releasing peptide in short children. Eur J Endocrinol 1996; 134: 716-719.
103. Korbonits M, Grossman AB. Growth hormone-releasing peptide and its analogues. Novel stimuli to growth hormone release. Trends Endocrinol Metab 1995; 6: 43-49.
104. Korbonits M, Trainer PJ, Besser GM. The effect of an opiate antagonist on the hormonal changes induced by hexarelin. Clin Endocrinol 1995; 43: 365-371.
105. Korbonits M, Little JA, Trainer PJ, Besser GM, Grossman AB. Analogues of growth hormone-releasing peptide (GHRP) do not affect the release of growth hormone-releasing hormone (GHRH) or somatostatin from the rat hypothalamus. J Endocrinol 1996; 148 (Suppl): 123.
106. Kraft LA, Baker PK, Doscher ME, Ricks CA. Effect of a synthetic growth hormone releasing hexapeptide on serum growth hormone levels in steers. J Anim Sci 1984; 59: 218.
107. Laron Z, Bowers CY, Hirsch D, Almonte AS, Pelz N, Keret R, Gil-Ad I. Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents. Acta Endocrinol 1993; 129: 424-429.
108. Laron Z Frenkel J, Gill-Ad, Klinger B, Imbim E, Wuthrich P, Boutignon F, Lengerts V, Deghenghi R. Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (Hexarelin). Clin Endocrinol 1994; 41: 539-541.
109. Laron Z. Growth hormone secretagogues. Drugs 1995; 50: 595-601.
110. Laron Z, Frenkel J, Deghenghi R, Anin S, Klinger B, Silbergeld A. Intranasal administration of the GHRP Hexarelin accelerates growth in short children. Clin Endocrinol 1995; 43: 631-635.
111. Leal Cerro A, Pumar A, Garcia-Garcia E, Dieguez C, Casanueva FF. Inhibition of growth hormone release after the combined administration of GHRH and GHRP-6 in patients with Cushing's syndrome. Clin Endocrinol 1994; 41: 649-654.
112. Leal-Cerro A, Garcia E, Astorga R, Casanueva FF, Dieguez C. Growth hormone (GH) responses to the combined administration of GH-releasing peptide 6 in adults with GH deficiency. Eur J Endocrinol 1995; 132: 712-715.
113. Lei T, Buchfelder M, Fahlbusch R, Adams EF. Growth hormone releasing peptide (GHRP-6) stimulates phosphatidylinositol (PI) turnover in human pituitary somatotroph cells. J Mol Endocrinol 1995; 14: 135-138.
114. Locatelli V, Grilli R, Torsello A, Cella SG, Wehrenberg WB, Muller EE. Growth hormone-releasing hexapeptide is a potent stimulator of growth hormone gene expression and release in the growth hormone-releasing hormone-deprived infant rat. Ped Res 1994; 36(2): 169-174.
115. Loche S, Cambiaso P, Carta D, Setzu S, Imbimbo BP, Borrelli P, Pintor C, Cappa M. The growth hormone-releasing activity of Hexarelin, a new synthetic hexapeptide, in short normal and obese children and in hypopituitary subjects. J Clin Endocrinol Metab 1995; 80: 674-678.
116. Loche S, Colao A, Cappa M, Bellone J, Aimaretti G, Farello G, Faedda A, Lombardi G, Deghenghi R, Ghigo E. The growth hormone response to Hexarelin in children: Reproducibility and effect of sex steroids. J Clin Endocrinol Metab 1997; 82: 861-864.
117. Locke W, Kirgis HD, Bowers CY, Abdo AA. Intracerebroventricular growth-hormone-releasing peptide-6 stimulates eating without affecting plasma growth hormone responses in rats. Life Sci 1995; 56: 1347-1352.
118. Maccario M, Arvat E, Procopio M, Gianotti L, Grottoli S, Imbimbo BP, Deghenghi R, Camanni F, Ghigo E. Metabolic modulation of the growth-hormone-releasing activity of hexarelin in man. Metabolism 1995; 44(1): 134-138.
119. Mallo F, Alvarez CV, Benitez L, Burguera B, Coya R, Casanueva FF, Dieguez C. Regulation of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 (GHRP6)-induced GH secretion in the rat. Neuroendocrinology 1993; 57: 247-256.
120. Malozowski S, Hao EN, Ren SG, Marin G, Liu L, Southers JL, Merriam GR. Growth hormone (GH) responses to the hexapeptide GH-releasing peptide and GH-releasing hormone (GHRH) in the cynomologus macaque: Evidence for non-GHRH-mediated responses. J Clin Endocrinol Metab 1991; 73: 314-317.
121. Massoud AF, Hindmrsh PC, Brook CG. Hexarelin induced growth hormone release is influenced by exogenous growth hormone. Clin Endocrinol 1995; 43: 617-621.
122. Massoud AF, Hindmarsh PC, Matthews DR, Brook CGD. The effect of repeated administration of hexarelin, a growth hormone releasing peptide, and growth hormone releasing hormone on growth hormone responsivity. Clin Endocrinol 1996; 44: 555-562.
123. Mazza E, Ghigo E, Goffi S, Procopio M, Imperiale E, Arvat E, Bellone J, Boghen MF, Muller EE, Camanni F. Effect of the potentiation of cholinergic activity on the variability in individual GH response to GHRH. J Endocrinol Invest 1989; 12: 795-798.
124. McCormick GF, Millard WJ, Badger TN, Bowers CY, Martin JB. Dose-response characteristics of various peptides with growth hormone-releasing activity in the unanesthetized male rat. Endocrinology 1985; 117: 97-105.
125. McDowell RS, Elias KA, Stanley MS, Burdick DJ, Burnier JP, Chan KS, Fairbrother WJ, Hemmonets RG, Mortensen DL, Rawson TE, Wvn WB, Clark RG, Somers TC. Growth hormone secretagogues: Characterization, efficacy, and minimal bioactive conformation. Biochemistry 1995; 92: 11165-11169.
126. Mericq V, Cassorla F, Garcia H, Avila A, Bowers CY, Merriam GR. Growth hormone (GH) responses to GH-releasing peptide and to GH-releasing hormone in GH-deficient children. J Clin Endocrinol Metab 1995; 80: 1681-1684.
127. Micic D, Popovic V, Kendereski A, Macul D, Casanueva FF, Dieguez C, Laron Z. Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clin Endocrinol 1995; 42: 191-194.
128. Momany FA, Bowers CY, Reynolds GA, Hong A, Newlander K. Conformational energy studies and in vitro and in vivo activity data on active GH releasing peptides. Endocrinology 1984; 114: 1531-1536.
129. Muccioli G, Ghe' C, Ghigo MC, Arvat E, Papotti M, Boghen MF, Deghenghi R, Ong H, Ghigo E. Growth hormone-releasing peptide receptors in human brain and pituitary gland. Fundam Clin Pharmacol 1996; 10(Suppl): 205.
130. Muller EE, Nistico' G, Eds. Brain Messenger and the Pituitary. San Diego: Academic Press, 1989.
131. Muruais J, Penalva A, Dieguez C, Casanueva FF. Influence of endogenous cholinergic tone and alpha-adrenergic pathways on growth hormone responses to His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the dog. J Endocrinol 1993; 138: 211-218.
132. Patchett AA, Nargunt RP, Tata JR, Chen MH, Barekat KJ, Johnston DBR, Cheng K, Chan WWS, Butler B, Hickey G, Jacks T, Schkeim K, Pong SS, Cheung LYP, Chen HY, Frezier E, Leung KH, Chiu SH, Smith RG. Design and biological activities of L-163,191 (MK-0677): A potent orally active growth hormone secretagogue. Proc Natl Acad Sci USA 1995; 92: 7001-7005.
133. Peino R, Cordido F, Penalva A, Alvarez V, Dieguez C, Casanueva FF. Acipimox-mediated plasma free fatty acid depression per se stimulates growth hormone (GH) secretion in normal subjects and potentates the response to other GH-releasing stimuli. J Clin Endocrinol Metab 1996; 81: 909-913.
134. Penalva A, Carballo A, Pombo M, Casanueva FF, Dieguez C. Effect of growth hormone (GH)-releasing hormone (GHRH), atropine, pyridostigmine, or hypoglycemia on GHRP-6-induced GH secretion in man. J Clin Endocrinol Metab 1993; 76: 168-171.
135. Penalva A, Pombo M, Carballo A, Barreiro J, Casanueva FF, Dieguez C. Influence of sex, age and adrenergic pathways on the growth hormone response to GHRP-6. Clin Endocrinol (Oxford) 1993; 38: 87-91.
136. Pihoker C, Middleton R, Reynolds GA, Bowers CY, Badger TM. Diagnostic studies with intravenous and intranasal growth hormone-releasing peptide-2 in children of short stature. J Clin Endocrinol Metab 1995; 80: 2987-2992.
137. th International Congress of Endocrinology, San Francisco 1996: 768.
138. Orth DN. Corticotropin-releasing hormone in humans. Endocr Rev 1992; 13: 164-191.
139. Pombo M, Barreiro J, Penalva A, Mallo F, Casanueva FF, Dieguez C. Plasma growth hormone response to growth hormone releasing hexapeptide (GHRP-6) in children with short stature. Acta Paediatr 1995; 84: 904-908.
140. Pombo M, Barreiro J, Penalva A, Peino R, Dieguez C, Casanueva FF. Absence of growth hormone (GH) secretion after the administration of either GH releasing hormone (GHRH), GH-releasing peptide (GHRP-6), or GHRH plus GHRP-6 in children with neonatal pituitary stalk transection. J Clin Endocrinol Metab 1995; 80: 3180-3184.
141. Pong SS, Chaung LYP, Dean DC, Nargunt RP, Patchett AA, Smith RG. Identification of a new G-protein-linked receptor for growth hormone secretagogues. Mol Endocrinol 1996; 10: 57-61.
142. Popovic V, Damjanovic S, Micic D, Petakov M, Dieguez C, Casanueva FF. Growth hormone (GH) secretion in active acromegaly after the combined administration of GH-releasing hormone and GH-releasing peptide-6. J Clin Endocrinol Metab 1994; 79: 456-460.
143. Popovic V, Damjanovic S, Micic D, Djurovic M, Dieguez C, Casanueva FF. Blocked growth hormone-releasing peptide (GHRP-6)-induced GH secretion and absence of the synergic action of GHRP-6 plus GH-releasing hormone in patients with hypothalamopituitary disconnection: Evidence that GHRP-6 main action is exerted at the hypothalamic level. J Clin Endocrinol Metab 1995; 80: 942-947.
144. Popovich V, Micic D, Damjanovich S, Djurovich M, Simic M, Gligorovic M, Dieguez C. Evaluation of pituitary GH reserve with GHRP-6. J Pediatr Endocrinol Metab 1996; 9: 289-298.
145. Ramos-Dias JC, Pimentel Filho F, Reis AF, Lengyel AMJ. Different growth hormone (GH) responses to GH-releasing peptide and GH-releasing hormone in hyperthyroidism. J Clin Endocrinol Metab 1996; 81: 1343-1346.
146. Renner U, Brockmeier S, Strasburger CJ, Lange M, Schopohl J, Muller OA, Werder K, Stelle GK. Growth hormone (GH)-releasing peptide stimulation of GH release from human somatotroph adenoma cells: Interaction with GH-releasing hormone, thyrotropin-releasing hormone, and octreotide. J Clin Endocrinol Metab 1994; 78: 1090-1096.
147. Rolla M, Andreoni A, Bellitti D, Cristofani R, Ferdeghini M, Muller EE. Blockade of cholinergic muscarinic receptors by pirenzepine and GHRH-induced GH secretion in the acute and recovery phase of anorexia nervosa and atypical eating disorders. Biol Psychiatr 1991; 29: 1079-1091.
148. Robinson BM, DeMott Friberg R, Bowers CY, Barkan AL. Acute growth hormone (GH) response to GH-releasing hexapeptide in humans in independent of endogenous GH-releasing hormone. J Clin Endocrinol Metab 1992; 75: 1121-1124.
149. th International Congress of Endocrinology, San Francisco 1996: 26.
150. Ross JRJM, Chew SL. Acquired growth hormone resistance. Eur J Endocrinol 1995; 132: 655-660.
151. Rudman D, Feller AG, Nagraj HS. Effects of human growth hormone in men over 60 years old. N Engl J Med 1990; 323: 1-6.
152. Sartor O, Bowers CY, Chang D. Parallel studies of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 and human pancreatic growth hormone-releasing factor-44-NH2 in rat primary pituitary cell monolayer culture. Endocrinology 1985; 116: 952-957.
153. Sartor O, Bowers CY, Reynolds GA, Momany FA. Variables determining the growth hormone response of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 in the rat. Endocrinology 1985; 117: 1441-1447.
154. Sartorio A, Conti A, Ferrero S, Spada A, Faglia G. GH responsiveness to repeated GHRH or Hexarelin administration in normal adults. J Endocrinol Invest 1995; 18: 718-722.
155. th International Congress of Endocrinology, San Francisco 1996: 285.
156. Sethumadhavan K, Veeraragavan K, Bowers CY. Demonstration and characterization of the specific binding of growth hormone-releasing peptide to rat anterior pituitary and hypothalamic membranes. Biochem Biophys Res Commun 1991; 178: 31-37.
157. Sirinathsinghji DJS, Chen HY, Hopkins R, Trumbauer M, Heavens R, Rigby M, Smith RG, Ven der Ploeg LHT. Induction of c-fos mRNA in the arcuate nucleus of normal and mutant growth hormone-deficient mice by a synthetic non-peptydil growth hormone secretagogue. Mol Neurosci 1995; 6: 1989-1992.
158. Smith RG, Cheng K, Pong SS, Hickey G, Jacks T, Butler B, Chan WWS, Chaung LYP, Judith F, Taylor J, Schoern WR, Wyvratt MJ, Fisher MH. A non-peptidyl GH secretagogue. Science 1993; 260: 1640-1643.
159. th International Congress of Endocrinology, San Francisco 1996: 287.
160. Thomas GB, Fairhall KM, Robinson ICAF. Activation of the hypothalamo-pituitary-adrenal axis by the growth hormone (GH) secretagogue, GH-releasing peptide-6, in rats. Endocrinology 1997; 138: 1585-1591.
161. Thorner MO, Vance ML, Rogol AD, Blizzard RM, Veldhuis JD, van Cauter E, Copinschi G, Bowers CY. Growth hormone-releasing hormone and growthg hormone-releasing peptide as potential therapeutic modalities. Acta Paediatr Scand 1990; 367(Suppl): 29-32.
162. Thorner MO, Hartman ML, Gaylinn BD et al. Current status of therapy with growth hormone-releasing neuropeptides. In: Savage MO, Bourgulgon J, Grossman AB, Eds. Front in Paediatr Neuroendocrinol. Oxford: Blakwell Scientific, 1994: 161-167.
163. Tuilpakov AN, Bulatov AA, Peterkova A, Elizarova GP, Volevodz NN, Bowers CY. Growth hormone (GH)-releasing effects of synthetic peptide GH-releasing peptide-2 and GH-releasing hormone (1-29NH2) in children with GH insufficiency and idiopathic short stature. Metabolism 1995; 44: 1199-1204.
164. Valcavi R, Dieguez C, Zini M, Muruais C, Casanueva F, Portioli I. Influence of hyperthyroidism on growth hormone secretion. Clin Endocrinol 1993; 38: 515-522.
165. Vance ML, Borges JLC, Kaiser DL, Evans WS, Furlanetto R, Thominet JL, Frohman LA, Rogol AD, MacLeod M, Bloom S, Rivier J, Vale W, Thorner MO. Human pancreatic tumor growth hormone-releasing factor (hp GRF-40): Dose-response relationship in normal man. J Clin Endocrinol Metab 1984; 58: 838-845.
166. Van der Berghe G, de Zegher F, Bowers CY, Wouters P, Muller P, Soetens F, Ulasselaers D, Schetz M, Verwaest C, Lauwers P, Bouillon R. Pituitary responsiveness to GH-releasing hormone, GH-releasing peptide-2 and thyrotropin-releasing hormone in critical illness. Clin Endocrinol 1996; 45: 341-351.
167. Veeragavan K, Sethumadhavan K, Bowers CY. Growth hormone-releasing peptide (GHRP) binding to porcine anterior pituitary and hypothalamic membranes. Life Sci 1992; 50: 1149-1155.
168. Walker RF, Yang SW, Bercu BB. Robust growth hormone (GH) secretion in aged female rats co-administered GH-releasing hexapeptide (GHRP-6) and GH-releasing hormone (GHRH). Life Sci 1991; 49: 1499-1504.
169. Walker RF, Yang AW, Masuda R, Hu CS, Bercu BB. Effects of growth hormone releasing peptides on stimulated growth hormone secretion in old rats. In: Bercu BB, Walker RF, Eds. Growth hormone II, Basic and Clinical Aspects. Springer-Verlag, New York, 1993: 167-192.
170. Wu D, Chen C, Katoh K, Zhang J, Clarke J. The effect of GH-releasing peptide-2 (GHRP-2 or KP 102) on GH secretion from cultured ovine pituitary cells can be abolished by a specific GH-releasing factor (GRF) receptor antagonist. J Endocrinol 1994; 140: 9-13.
171. Wu D, Chen C, Zhang J, Katoh K, Clark I. Effects in vitro of new growth hormone releasing peptide (GHRP-1) on growth hormone secretion from ovine pituitary cells in primary culture. J Neuroendocrinol 1994; 6: 185-190.
172. Yagi H, Kaji H, Sato M, Okiimura Y, Chihara K. Effect of intravenous or intracerebroventricu-lar injections of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 on GH release in conscious, freely moving male rats. Neuroendocrinology 1996; 63: 198-206.